EVOK - Evoke Pharma Inc
IEX Last Trade
4.9
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 04:10:03 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$4.90
0.00
0.00%
Fundamental analysis
42%
Profitability
50%
Dept financing
14%
Liquidity
50%
Performance
40%
Performance
5 Days
-1.21%
1 Month
11.62%
3 Months
-3.54%
6 Months
842.31%
1 Year
349.67%
2 Year
87.02%
Key data
Stock price
$4.90
DAY RANGE
$4.15 - $4.99
52 WEEK RANGE
$0.44 - $12.32
52 WEEK CHANGE
$345.45
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: David A. Gonyer
Region: US
Website: evokepharma.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: evokepharma.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Evoke Pharma, Inc. is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Recent news